Epigral Reports Q4FY25 PAT Growth of 13% to Rs 870 Million

07 May 2025 CW Team

Reflecting its strong performance, the company’s balance sheet strengthened further in FY25. Return on capital employed (ROCE) rose to 25% from 18% in FY24, and Net Debt/EBITDA improved significantly to 0.7x from 2.0x. Credit rating was upgraded to CRISIL AA from CRISIL AA-.

Chairman and Managing Director Maulik Patel stated, “We closed FY2025 with the highest-ever revenue of Rs 25.65 billion, a 33% growth over the previous year. This was driven by an 11% volume increase, especially in high-value products. Our Derivatives & Specialty segment grew 24% and now contributes 54% to total revenue, up from 45% in FY24.”

The company plans to expand its CPVC and Epichlorohydrin (ECH) capacities, which are expected to come online in H1FY27 and contribute thereafter. The integrated complex is expected to further benefit once these projects reach full capacity.

Dividend Update:

Epigral’s board proposed a final dividend of Rs 3.5 per equity share, bringing the total dividend for FY2025 to Rs 6.0 per share (60% of the face value of Rs 10).

Strategic & financial highlights for FY2025:

Credit rating upgraded to CRISIL AA.
Capital expenditure stood at Rs 1.95 billion in FY2025.
Successfully raised Rs 3.33 billion via QIP to support growth.
CPVC Resin capacity expanded to 75,000 TPA; approved to double to 150,000 TPA.
Epichlorohydrin capacity to double to 100,000 TPA.
Commissioned CPVC Compound and Chlorotoluenes Value Chain facilities.

Q4FY25 operational & financial highlights:

Revenue grew 20% YoY to Rs 6.31 billion.
Derivatives & Specialty segment’s revenue contribution rose to 52% from 48% in Q4FY24.
EBITDA increased 12% to Rs 1.73 billion, with a margin of 28%.
PAT rose 13% to Rs 870 million.
Captive chlorine usage increased to 76%.

FY2025 operational & financial summary:

Sales volume grew 11%, with overall capacity utilisation at 81% (vs 78% in FY24).
Highest-ever revenue at Rs 25.65 billion, up 33% YoY.
Derivatives & Specialty business contributed 54% to revenue.
EBITDA rose 48% to Rs 7.11 billion (vs Rs 4.81 billion in FY24).
EBITDA margin improved to 28% from 25%.
PAT surged 82% to Rs 3.57 billion.

(BSE)

Image Source: Image Generated by ChatGPT

Epigral Limited, a leading integrated chemical manufacturer in India, announced its financial results for the quarter ended March 31, 2025. The company reported a 13% year-on-year rise in profit after tax (PAT) at Rs 870 million in Q4FY25, compared to Rs 770 million in Q4FY24. Revenue for the quarter stood at Rs 6.31 billion, up 20% from Rs 5.26 billion in the same quarter last year.Reflecting its strong performance, the company’s balance sheet strengthened further in FY25. Return on capital employed (ROCE) rose to 25% from 18% in FY24, and Net Debt/EBITDA improved significantly to 0.7x from 2.0x. Credit rating was upgraded to CRISIL AA from CRISIL AA-.Chairman and Managing Director Maulik Patel stated, “We closed FY2025 with the highest-ever revenue of Rs 25.65 billion, a 33% growth over the previous year. This was driven by an 11% volume increase, especially in high-value products. Our Derivatives & Specialty segment grew 24% and now contributes 54% to total revenue, up from 45% in FY24.”The company plans to expand its CPVC and Epichlorohydrin (ECH) capacities, which are expected to come online in H1FY27 and contribute thereafter. The integrated complex is expected to further benefit once these projects reach full capacity.Dividend Update:Epigral’s board proposed a final dividend of Rs 3.5 per equity share, bringing the total dividend for FY2025 to Rs 6.0 per share (60% of the face value of Rs 10).Strategic & financial highlights for FY2025:Credit rating upgraded to CRISIL AA.Capital expenditure stood at Rs 1.95 billion in FY2025.Successfully raised Rs 3.33 billion via QIP to support growth.CPVC Resin capacity expanded to 75,000 TPA; approved to double to 150,000 TPA.Epichlorohydrin capacity to double to 100,000 TPA.Commissioned CPVC Compound and Chlorotoluenes Value Chain facilities.Q4FY25 operational & financial highlights:Revenue grew 20% YoY to Rs 6.31 billion.Derivatives & Specialty segment’s revenue contribution rose to 52% from 48% in Q4FY24.EBITDA increased 12% to Rs 1.73 billion, with a margin of 28%.PAT rose 13% to Rs 870 million.Captive chlorine usage increased to 76%.FY2025 operational & financial summary:Sales volume grew 11%, with overall capacity utilisation at 81% (vs 78% in FY24).Highest-ever revenue at Rs 25.65 billion, up 33% YoY.Derivatives & Specialty business contributed 54% to revenue.EBITDA rose 48% to Rs 7.11 billion (vs Rs 4.81 billion in FY24).EBITDA margin improved to 28% from 25%.PAT surged 82% to Rs 3.57 billion.(BSE)Image Source: Image Generated by ChatGPT

Infrastructure Urban

10 Mar 2026

ABB to Invest Rs 6.25 Billion to Expand India Manufacturing

ABB recently announced plans to invest approximately Rs 6.25 billion ($75 million) in India during 2026 to expand its manufacturing footprint and research and development capabilities. The investment follows more than $35 million spent in 2025 and reflects the company’s continued focus on strengthening its ‘local-for-local’ strategy in the country.The investment will support ABB’s Electrification, Motion and Automation businesses and expand manufacturing capacity for infrastructure sectors such as renewable energy, metro rail, data centres and industrial applications. Approximately 300..

Equipment

10 Mar 2026

Six WOLFF Cranes Handle 60,000 m³ Concrete for German Hospital

Six WOLFF tower cranes are playing a key role in constructing a new hospital complex in Memmingen, Germany, supporting large-scale material handling for the project. The facility is being built on a 7.7-hectare site and will feature six floors, around 480 beds and a gross floor area exceeding 75,000 sq m.Building shell works began recently in February 2025. One WOLFF 6531.12 Cross crane supported early site preparation before being dismantled in autumn 2025, while five remaining cranes continue operations. Over an average deployment period of 16 months, the cranes are expected to move approxim..

Equipment

10 Mar 2026

REC Funds Rs 115.6 Million CSR Support for Bihar Eye Hospital

REC recently committed Rs 115.6 million under its Corporate Social Responsibility (CSR) programme for the procurement of clinical and non-clinical equipment at Sankara Eye Hospital in Saharsa, Bihar. The initiative aims to strengthen healthcare infrastructure and improve access to specialised eye care services in the region.A Memorandum of Agreement (MoA) was recently signed between Pradeep Fellows, Executive Director (CSR), REC Limited, and Wg Cdr V. Shankar (Retd), Trustee and Executive Director of Sankara Eye Hospital, at the REC office in the SCOPE Complex, New Delhi.The support is expecte..